Thomas Burns
Vermögen: 2 Mio $ am 31.05.2026
Vermögen: 2 Mio $ am 31.05.2026
Thomas M.
Burns is currently a Non-Executive Director at LAVA Therapeutics NV since 2025.
Formerly, Mr. Burns was an Independent Director at Acorda Therapeutics, Inc. from 2023 to 2024 and served as Chief Financial Officer & Senior VP-Finance at XOMA Royalty Corp.
from 2015 to 2026.
Education includes an MBA from Golden Gate University conferred in 1999 and an undergraduate degree from Santa Clara University conferred in 1995.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 25.03.2026 | 36’209 ( 0.29% ) | 2 Mio $ | 31.05.2026 | |
| 19.09.2025 | 2’000 ( 0.2% ) | 50 910 $ | 31.05.2026 | |
| 19.09.2025 | 2’000 ( 0.11% ) | 50 680 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| LAVA THERAPEUTICS N.V. | Direktor/Vorstandsmitglied | 07.11.2025 |
| Unternehmen | Position | Ende |
|---|---|---|
| XOMA ROYALTY CORPORATION | Finanzdirektor/CFO | 12.01.2026 |
| ACORDA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 21.08.2024 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
XOMA Royalty Corp.
XOMA Royalty Corp. Pharmaceuticals: MajorHealth Technology Discovers and develops antibody therapeutics | Health Technology |
Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops, manufactures and markets therapeutic products for neurological disorders | Health Technology |
Golden Gate University
Golden Gate University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Santa Clara University
Santa Clara University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LAVA Therapeutics NV
LAVA Therapeutics NV Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops antibodies for the treatment of cancer | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen